NCT03667820 - Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Osimertinib

Osimertinib 80mg tablet to be taken once daily.

RADIATION

SABR

Stereotactic Ablative Radiation (SABR)

Trial Locations (2)

University of Texas Southwestern Medical Center, Dallas

City of Hope Medical Center, Duarte